General Motors
BP
Ford Motor Company
AstraZeneca
DaimlerChrysler
CNN
General Electric
US Senate
Credit Suisse First Boston
Volkswagen
Siemens
Philip Morris
AstraZeneca
Bloomberg
Verizon
AT&T
BP
Philips
FIAT
Nestle
General Dynamics
Lloyds
Hewlett Packard
BP
Pfizer
ABN Amro
UBS Warburg
Merrill Lynch
New York Stock Exchange
Royal & SunAlliance
The Economist
AstraZeneca
France Telecom
Boeing
Lafarge
Safeway
People's Republic of China's
BBC
Ministry of Agriculture
AT&T
Nordea
Tesco
Pfizer
Philips
Sybase
Sprint
AT&T
New York Life Insurance
Canon USA
Novell
Ericsson
Danske Bank
EDS
Philip Morris International
Royal & SunAlliance
Novartis
Hewlett Packard
Credit Lyonnais
Siemens
Sun Microsystems
British American Tobacco
Norsk Hydro
AstraZeneca
Skanska
BAE Systems
Philips
Kodak
The Royal Mail Group
Henkel
Bank of Montreal
Danske Bank
BMW
US Department of Defense
Kronos Corporation
Fujitsu Technology Services
Zurich Financial Services
Halliburton
BBC
T-Mobile
Blue Cross/Blue Shield of Massachusetts
T-Mobile
US State Department
Channel 4 Corporation
VHA
Burges Salmon
Motorola
British Telecom
Ferrari
Deloitte & Touche
BBC
PA Consulting
US Army
BP
US Department of Defense
UK Department of Trade & Industry
Ingersoll-Rand
General Motors
EMC Corporation
US Department of Commerce
Encana Corporation
IEEE
Hewitt Associates LLC
HEALTHvision
Paramount
Lexmark
US State Department
Vodafone Omnitel
AstraZeneca
Nestle
US Department of Defense
Nestle
JD Edwards
MOL
3
Ingersoll-Rand
Nestle
PricewaterhouseCoopers
Macmillan Publishing
Nestle
Vodafone Omnitel
Nomura
US State Department
General Motors
Reed Elsevier
Lloyds
Dow Chemical Company
HM Revenue & Customs
General Electric
Lloyds
Siemens Power Generation
Texas Instruments
Forrester Research
Philips
McData
Wall Street Journal
Lloyds
NASA
SCA
Reuters
The McGraw-Hill Companies
ITN
Sun Microsystems
AstraZeneca
IBM NICA
Forbes.com
Nissan North America, Inc.
Toyota Motor
The McGraw-Hill Companies
Fox Sports
New York Life Insurance
Society of Petroleum Engineers
US Department of Energy
3
European Commission
Telecom Italia
Harrah's
AXA
Sybase
Napster
Sun Microsystems
Oracle
Compuware
3
US State Department
Olympus
ARM
Siemens
Taylor & Francis
Federal Express
Nissan Motor
Milward Brown Precis
Federal Government of Canada
UK Home Office
HM Revenue & Customs
3
Harvard Business School
AstraZeneca
Britvic Softdrinks
MOL
3
Macmillan Publishing
UK Department of Trade & Industry
Allianz Life Insurance Co
Swiss Army
Parliament of Singapore
VMS
General Motors
Britvic Softdrinks
Singapore Police Force
Sony Music
Ericsson
Hewlett Packard
GSA Advantage!
Kaiser Permanente
Sun Microsystems
Stanford Business School
Johns Hopkins
Wachovia
Standard Life Insurance
Raytheon
Ericsson
Commerzbank
US Department of Commerce
ABN Amro
3
Allstate Insurance
State of Washington
Napa Valley County
Henkel
Texas Department of Transportation
AstraZeneca
3
UK Department of Trade & Industry
Credit Lyonnais
American HomePatient
Swiss Army
TIBCO
Sharper Image
Xerox
America Online
Lockheed Northrop Grumman
Philips
Dow Chemical Company
General Motors
Draeger Medical
Sutter Health
Kenyan AIDS Clinic
University of Washington
State of Minnesota
World Wildlife Fund
Autonomy Group Customers
 
News
Events
RSS Feeds
Press Release Archives
For Financial News, please see the Investors section of the website.

News CARDIFF AND SEWARD C... | AUTONOMY DELIGHTED T... | NEW YORK LIFE UPGRAD...
Press Release
Related Events
Related Case Studies
Related Resources

Autonomy Delighted To Announce Launch Of Isabel

Online clinical decision support and information system is launched to help prevent misdiagnosis in children

CAMBRIDGE, UK-June 17, 2002- Autonomy Corporation plc (Nasdaq: AUTN; LSE: AU.; Nasdaq Europe: AUTN), today announced the launch of the ISABEL clinical decision support system for medical professionals, which is based on Autonomy's sophisticated infrastructure software. ISABEL aims to bridge the knowledge gap that exists in many health systems, notably that most of the critical knowledge and experience resides with senior consultants in hospitals and not with the doctors who first examine patients.

ISABEL is a free of charge online clinical decision support system that is available to all registered health professionals, providing critical support in areas such as diagnosis, treatment guidelines and shared experience. ISABEL, which currently concentrates on pediatrics, also offers an annotated image library, allowing users to compare their patients' visible symptoms with those available on the site, and consequently assist them in making a potentially life-saving diagnosis.

Autonomy donated its pattern-matching software to the Isabel Medical Charity to enable fast, accurate assistance for all medical professionals, who often do not have the benefit of the more specialist knowledge required to make accurate diagnoses. Applying Autonomy's pattern matching software to medical textbooks enables ISABEL to deliver a fast and practical differential diagnostic tool. When using ISABEL the doctor simply needs to type in a patient's symptoms from which the Autonomy software will extract the key ideas before searching ISABEL's extensive library of content to find a similar combination of symptoms - and consequently suggesting a range of relevant diagnoses. In essence, this mimics the doctor's existing and intuitive diagnostic process, the difference being that the system's base of textbook knowledge is far larger than can readily be stored in the human brain. Its performance is also unaffected by tiredness and overwork.

The charity's goals are primarily to reduce the number of children becoming seriously ill as a result of incorrect or delayed diagnosis, and to increase survival chances of sick children by ensuring that suitable treatment is administered immediately as a result of ready availability of expert guidelines compiled by acknowledged experts in specific fields of medicine. Even before its public launch, ISABEL has attracted over 3,000 users and already has extensive support from within the medical profession and the Department of Health.

Mike Lynch, Founder and CEO of Autonomy Corporation today commented, "Autonomy is delighted to be supporting the Isabel Medical Charity. ISABEL will offer a critical resource to help doctors reduce the risk of error in the diagnosis of children's illnesses, and encourage dissemination of knowledge within the medical profession".

Jason and Charlotte Maude, founders of The Isabel Medical Charity today commented, "ISABEL has only been made possible by the use of Autonomy's software and as a small charity, we could not have developed the system in such a short space of time without the generous donation from Autonomy for which we are very grateful."

Autonomy's unique Intelligent Data Operating Layer (IDOL) integrates unstructured, semi-structured and structured information from multiple repositories through an understanding of the content. At the heart of Autonomy's software is its ability to analyze text and voice (in any language) and identify and rank the main concepts within it. It then automatically categorizes, links, personalizes and delivers that information. Autonomy's infrastructure technology is used to automate operations within enterprise information portals, customer relationship management, knowledge management, business intelligence and e-business applications, among others.

About Autonomy

Autonomy Corporation plc (Nasdaq: AUTN; Nasdaq Europe: AUTN; LSE: AU.) is a global leader in infrastructure software for the enterprise. Autonomy's technology powers applications dependent upon unstructured information including e-commerce, customer relationship management, knowledge management, enterprise information portals, enterprise resource planning and online publishing. Autonomy's customer base includes more than 550 global companies, including Hutchison 3G, Channel 4, Deutsche Bank, AT&T, AstraZeneca, BAE Systems, Ford, Ericsson, General Motors, Lucent, Royal Sun Alliance, Sun Microsystems and public sector agencies including the UK Government's Department of Trade and Industry, NASA, the US Department of Defense and the US Department of Energy. Strategic reseller and OEM partners include leading companies such as BEA, Business Objects, Computer Associates, Hewlett Packard, IBM Global Services, Oracle, Vignette and Sybase. The company has offices in North America, Europe, Asia and Australia and is on the Web at http://www.autonomy.com/

About ISABEL

Jason and Charlotte Maude founded the project in July 1999 together with Dr Joseph Britto, Paediatric Intensive Care Consultant at St Mary's Hospital, Paddington, London. Three months prior to this, the Maudes' 3-year-old daughter, Isabel, had spent a month in Intensive Care suffering multiple organ failure and cardiac arrest and a further month in a High Dependency ward. All this because her local A&E department and GP had failed to recognise her critical, life-threatening symptoms following chicken pox. Against all odds, Isabel's sole legacy is a large wound requiring extensive plastic surgery. During their time in hospital, the idea of a diagnostic tool slowly evolved during conversations between the Maudes and Dr Britto, who gradually gathered the support of a number of high profile doctors from hospitals around the country to make up the ISABEL team. The Isabel Medical Charity received charitable status in April 2000. Its registered office is in London. Further information is on the web at http://www.isabel.org.uk/

Caution Concerning Forward-Looking Statements

With the exception of historical information, the matters set forth in this news release are forward-looking statements that involve risks and uncertainties. A number of important factors could cause actual results to differ materially from those in the forward-looking statements. These factors include, among others, technology risks, including dependence on core technology; fluctuations in quarterly results; dependence on new product development; rapid technological and market change; reliance on sales by others; management of growth; dependence on key personnel; rapid expansion; growth of the Internet; financial risk management; and future growth subject to risks. These factors and other factors which could cause actual results to differ materially are also discussed in the company's filings with the United States Securities and Exchange Commission, including Autonomy's Annual Report on Form 20-F and Registration Statements on Form F-1.

For more information, please contact:
Ian Black
Autonomy Corporation plc
+44 (0) 1223 448 000
ianb@autonomy.com
Jason/Charlotte Maude
ISABEL Medical Charity
+44 (0) 208 748 4330
info@isabel.org.uk

This is a selection of our forthcoming events, please visit our seminars page for more information.

Automatic Hyperlinks provided by IDOL Server 7

This is a small selection of the Autonomy case studies available, please visit our publications site at http://publications.autonomy.com/ for more information.

Automatic Hyperlinks provided by IDOL Server 7

+1 415 243 9955

Company
Technology
Functionality
Products
Solutions
Services
Customers
Partners
News & Events